Revelation Partners provides flexible capital solutions for healthcare companies and their shareholders. The firm manages $1.5 billion in assets, has over 50 active portfolio companies, and claims a total value of exited companies exceeding $100 billion.

Revelation Partners

Revelation Partners provides flexible capital solutions to the healthcare ecosystem. We specialize in providing liquidity for illiquid, private holdings to eliminate friction and capital to accelerate growth. We invest broadly across all healthcare sub-sectors, including medical devices, life science tools and diagnostics, biopharmaceuticals, healthcare technology, and healthcare services. With decades of investing experience, deep sector expertise, an extensive industry network, and over $1.5bn of committed capital, Revelation Partners is a trusted partner to healthcare investors, companies, and funds.

SomaLogic

ClearCorrect

NeuroPace

We’re thrilled to congratulate our portfolio company Vertos Medical on its acquisition by global medical technologies leader Stryker! Vertos’ innovative procedure for lumbar spinal stenosis — which is a leading cause of pain and disability — is minimally invasive with high lasting relief rates and reduced recovery times. 

“Allowing patients to get back to what matters most to them is what matters most to us,” said Eric Wichems, Vertos Medical’s Chief Executive Officer. “Stryker’s mission and focus on interventional solutions provides an opportunity to further improve patients' quality of life.” 
 
Read more about the acquisition agreement here: https://lnkd.in/dsJ85nU9

Check out our latest blog post, written by Garrett B., where we take a deep dive into into the #fundraising environment for emerging managers, and assess why emerging managers in #healthcare stand to disproportionately benefit from building a track record of distributions via a secondary toolkit:

https://lnkd.in/g8jc_vfu

Interested in learning about secondary transactions in healthcare private equity? Read our latest white paper written in partnership with Darren Schluter and Danny Schuster from PJT Partners Park Hill:

#privateequity #secondaries #healthcare

https://lnkd.in/gyXHWaC9

Check out our interview with Gerald Cooper for our blog series 
"Secondary Spotlight," where we interview some of the leading secondary advisors in the industry:

https://lnkd.in/gdCsyRZu

In this fifth (and final) release in a series of interviews with successful figures in the venture capital secondary market, Derek Minno talks with Michael Boggs, Managing Partner at Revelation Partners, on healthcare secondaries.

“Last year we invested over $190 million across all healthcare segments, which is 6x what we did in our first year as Revelation, so the dynamic has really changed, and the market is really exploding in terms of growth in every dimension,” Boggs said.

This article features Derek's takeaways from the conversation along with his own insights, as written by Derek himself. 

Take a look!

#Secondaries #Secondary #SecondaryMarket #AlternativeInvestments #PrivateMarkets #Venture #VentureCapital #VC

"Immuno-oncology company Nouscom AG has extended a Series C financing round to raise $82m (€75.8m) as it looks to advance its pipeline of personalized and off-the-shelf cancer vaccines."

https://lnkd.in/gJqRrzvy

We're thrilled to welcome Courtney Munley and Paden Rasmussen to the team, and also celebrate the growth of internal talent: 

https://lnkd.in/grbfdDfF

Check out our interview with Todd Miller for our new blog series 
"Secondary Spotlight," where we interview some of the leading secondary advisors in the industry:

https://lnkd.in/gjbq3Y_3

msh id	COM:REVELATION-PARTNERS
symbol	-
name	Revelation Partners
homepage url	https://revelation-partners.com
country	US
sector	Financial Services & Finance
industry	Investment Management
market	PRIVATE
employee count	-
crunchbase url	-
linkedin url	https://www.linkedin.com/company/revelation-partners
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

REVE

COM:REVELATION-PARTNERS

Revelation Partners

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-